首页> 外国专利> INHIBITION OF CORONAVIRUS (COVID-19) INFECTION BY MEANS OF APIVIRINE EXTRACT - DICHROSTACHYS GLOMERATA

INHIBITION OF CORONAVIRUS (COVID-19) INFECTION BY MEANS OF APIVIRINE EXTRACT - DICHROSTACHYS GLOMERATA

机译:抑制冠状病毒(Covid-19)感染通过亚哌啶提取物 - Dichrostachys Glomerata

摘要

APIVIRINE, extracted from Dichrostachys glomerata, is an antiviral drug made up of: gallic tannins, catechic tannins, alkaloids, flavonoids, saponosides, anthocyanins, leucoanthocyanins, steroids and terpenes, which together exhibit anti-COVID-19 activity. It can be used to cure and prevent coronavirus disease in symptomatic and asymptomatic patients and all exposed persons. Toxicological tests on rats are conclusive: APIVIRINE is non-toxic. The starting dose in cases requiring respiratory assistance is 12 capsules each containing 350 mg (orally or through a tube) of APIVIRINE powder obtained by incorporating 500 mg of pure lyophilised extract. Said dose is given three times a day in accordance with the half-life of APIVIRINE (four hours). For less severe cases and asymptomatic cases, the dose is three capsules three times a day and, for prevention, the dosage is one to two capsules three times a day. The absorption of APIVIRINE leads the coronavirus disappearing.
机译:从Dichrostachys Glomerata中提取的亚哌利林是一种由以下组成的抗病毒药物:Gallic Tannins,Tanchic Tannins,生物碱,类黄酮,皂苷,花青素,白蒽酸锌,类固醇和Terpenes,它们一起出现抗Covid-19活性。 它可用于治愈和预防症状和无症状患者的冠状病毒病和所有暴露的人。 对大鼠的毒理学试验是结论性的:亚西韦无毒。 在需要呼吸辅助的情况下的起始剂量是通过掺入500mg纯的冻干提取物而获得的亚哌啶粉末的350mg(口服或通过管)。 根据亚哌利的半衰期(4小时),每天给予所述剂量三次。 对于不太严重的病例和无症状的病例,剂量为3次胶囊,每天三次,用于预防,剂量为每天三次胶囊。 亚哌利林的吸收导致冠状病毒消失。

著录项

  • 公开/公告号WO2021224660A1

    专利类型

  • 公开/公告日2021-11-11

    原文格式PDF

  • 申请/专利权人 AGON ACHIDI VALENTIN;

    申请/专利号WO2020IB54304

  • 发明设计人 AGON ACHIDI VALENTIN;KINNOUDO CELESTIN;

    申请日2020-05-07

  • 分类号A61P31/14;A61K36/48;

  • 国家 IB

  • 入库时间 2022-08-24 22:29:36

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号